BGPT: Author Review: Tiffany Desouza

Explore by Goal

Quick Explanation Copied

Tiffany DeSouza — scientific signal (from available work list)

DeSouza’s publication footprint (per provided OpenAlex snippet) clusters strongly around adipose biology/thermogenesis and cell/tissue modeling & translational preclinical systems, with notable visibility for adipocyte-subtype development and thermogenic regulation via LINC00473. Examples include , and the LINC00473 thermogenic regulation study in Nature Metabolism: .

Quick caution (skeptical note)

A h-index/citation snapshot does not prove methodological rigor for any specific paper; rigorous assessment requires reading the full methods (controls, replication, model limitations, statistics, and preregistration where applicable).

Long Explanation

BGPT Author Scientific Review — Tiffany DeSouza

Evidence basis: the provided OpenAlex-derived work list (titles + DOIs where present) and citation counts shown in your input.

1) Publication/citation landscape (from provided snippet)

The following chart uses only the cited_by_count values explicitly present in your provided OpenAlex snippet for several top works.

Raw numbers used (from input): { 10.1056/NEJMoa1505517:586, 10.1016/j.ccell.2016.03.008:302, 10.1073/pnas.1906512116:150, 10.1182/blood-2017-11-818617:121, 10.1038/s42255-020-0205-x:119, 10.1126/scitranslmed.aay4145:103, 10.1038/s41467-021-27190-y:85 }

2) Scientific focus inferred from the provided work list (no extra claims)

Human adipocyte biology & thermogenesis: e.g., adipocyte subtype repertoire development in PNAS and thermogenic regulation by LINC00473 in Nature Metabolism .
Adipose remodeling and metabolic disease relevance: e.g., PAPPA-mediated adipose remodeling and protection against gestational diabetes (Sci Transl Med) .
Preclinical translation tools and models: a public xenograft repository enabling “randomized phase II-like trials” (Cancer Cell) .
Cancer immunobiology/oncogenesis in vivo (also present in the list): e.g., RhoA G17V sufficiency for autoimmunity and T-cell lymphomagenesis in mice (Blood) .

3) Scientific strength: what the evidence supports (and what it cannot)

Supported by the provided list:

The selected examples indicate engagement with mechanistic molecular biology (lncRNA regulation, progenitor multipotency signaling, cAMP responsiveness) including LINC00473 in human thermogenic adipocytes .
The list also includes systems for translational preclinical testing, such as the public xenograft repository work .

Not provable from the provided input:

Whether the mechanistic claims are causal vs. correlational in each paper cannot be verified without full-text methods/results (e.g., genetic rescue, orthogonal perturbations, blinding, replication depth, and statistical correction strategies).
Whether reported “human” relevance is driven by sufficiently powered cohort sizes, tissue-of-origin controls, and consistent cell-type gating cannot be confirmed from titles/DOIs alone.
Citation counts (even if high) can reflect community fit, model usefulness, or platform visibility, not necessarily superior rigor in every included study.

Most plausible blind spot from the limited evidence here:

The list mixes adipose/thermogenic biology with cancer/inflammation and preclinical repositories. That breadth can be legitimate interdisciplinary strategy, but it also increases the burden of domain-specific rigor across model systems; verifying rigor requires paper-by-paper method inspection.

4) “Evidence-strength map” for the provided anchor papers

This section keeps scope strictly to the information available in your input (titles/DOIs and brief OpenAlex abstracts where present). It does not rate rigor beyond what can be inferred without reading the full text.

Caveat: this proxy is only a label for the snipped abstract-level informativeness present in your input—not a substitute for full methods scrutiny.

5) What would most improve scientific confidence (skeptical checklist)

For mechanistic adipocyte papers (e.g., LINC00473, PAPPA, progenitor multipotency):

Demand orthogonal perturbations (independent genetic/biochemical ways to change the same pathway) and rescue experiments that restore the phenotype.
Check whether human cell-type identity is verified with multiple markers and whether differentiation direction is constrained by appropriate controls.
Verify whether reported pathway links (e.g., cAMP responsiveness) are demonstrated at both molecular and phenotypic levels.

For translational/preclinical resource papers (e.g., xenograft repository):

Assess model bias and representativeness (tumor heterogeneity, passage effects, and selection criteria).
Confirm the practical equivalence of “randomized phase II-like” framing: randomization method, endpoints, and handling of missing/failed engraftments.

General reproducibility red flags to seek:

Non-blinded quantification, single-model reliance, and underpowered cohort design.
Selective reporting (e.g., emphasizing supportive endpoints while underreporting null effects).

Next step (optional): run a full paper-grounded audit

If you want, BGPT can iteratively open and evaluate the full-text methods for the specific anchor DOIs above (controls, effect sizes, replication, statistics) and generate a paper-by-paper rigor critique.

Feedback:

Updated: May 01, 2026